Senseonics Aktie News

Kombination von einjährigem kontinuierlichem Glukosemonitoring mit automatisierter Insulinabgabe zur weiteren Vereinfachung des Diabetesmanagements für Patienten. Bringt Eversense 365 in die wachsende Community der iLet Bionic Pancreas‑Nutzer. Plan für die kommerzielle Markteinführung des integrierten Systems im Q4 2026. GERMANTOWN, Md., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, I...

Eversense 365 delivered favorable glucometrics compared to other open and closed loop systems, validating the one-year CGM's differentiated approach and high performance

GERMANTOWN, Md., June 01, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable Continuous Glucose Monitoring (CGM) Systems for people with diabetes, today highlights two key company events during the 86th Scientific Sessions of the American Diabetes Association (A...

Senseonics Holdings, Inc. Common Stock NASDAQ: SENS raised its full-year 2026 revenue outlook after reporting first-quarter growth tied to adoption of its Eversense 365 continuous glucose monitoring system and the integration of its U.S. commercial organization.

Generated Q1 revenue of $11.7 million, an increase of 87% year-over-year Expect full-year revenue in the range of $60M - $64M (previously $58M to $62M) Strong strategic and commercial progress, including the launch of Eversense® 365 in Europe Raised $100M+ in equity and debt financing to support commercial strategy and pipeline GERMANTOWN, MD., May 07, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdin...

GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the design, development and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced the closing of its previously announced underwritten public offering of $92 million of shares of its common...

GERMANTOWN, Md., May 04, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS) a medical technology company focused on the design, development and commercialization of glucose monitoring products designed to transform lives in the global diabetes community, announced that it has entered into a Second Amendment to the Loan and Security Agreement with Hercules Capital, Inc. (NYSE: HTGC).